August 2019
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference focused on the key issues for biosimilar use in the NHS.
It followed NHS England’s commitment to reduce spending on medicines by £300m by 2021 through increased use of biosimilars, as outlined in the Commissioning framework for biological medicines.
Delegates considered the priorities for commissioners in reducing spending on medicines and addressing unwarranted variation in biosimilar use, including the impact of prescribing incentive schemes such as gain share agreements.
Attendees assessed how engagement with clinical staff can be improved as well as improving patient awareness of biosimilars, and how best to inform patients and include them in decisions around switching treatments.
Attendees also considered the priorities for encouraging the development of new biosimilars in the UK and promoting the uptake of new biosimilars in the NHS.
The agenda included further sessions on the regulation of biosimilars and the future relationship between the European Medicines Agency and the MHRA, and provided an opportunity to discuss how biosimilars should be regulated in the UK after Brexit.
